Health Care/Hospital

MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY

* In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will enhance biological and molecular understanding of various pathologies. MILAN, June 26, 2025 /PRNewswire/ -...

2025-06-27 10:46 2128

WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity

SHANGHAI, June 26, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is delighted to announce that its Nantong site (Phase I) has been recognized as the Popula...

2025-06-27 08:00 2667

NEW SINGAPORE STUDY TO ASSESS GROWING PREVALENCE AND IMPACT OF FOOD ALLERGIES

Landmark four-year joint study led by NUH and NUS Medicine, in collaboration with KKH, NUP and SSHSPH, is the first and largest to involve over 2,000 children in addressing food allergies SINGAPORE, June 26, 2025 /PRNewswire/ -- A group of clinicians and researchers from theNational University H...

2025-06-26 23:32 2366

SineuGene's SNUG01 Receives FDA Orphan Drug Designation for ALS

BEIJING, June 26, 2025 /PRNewswire/ -- SineuGene Therapeutics, a clinical-stage biotechnology company focused on gene therapies for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its gene therapy, SNUG01, for the trea...

2025-06-26 22:04 1876

Porton Advanced and EVA Pharma Sign MOU to Expand CAR T-Cell Therapy Access in The Middle East and Africa

A new era of personalized gene therapy for Leukemia patients in Egypt, Saudi Arabia, and beyond. SUZHOU, China and CAIRO, June 26, 2025 /PRNewswire/ -- Porton Advanced Solutions, a global leading cell and gene therapy CDMO service provider, andEVA Pharma, one of the leading pharmaceutical compan...

2025-06-26 21:00 1832

Ubie Announces Cumulative Total Funding of Over $125M as US Efforts Target Expansion into Generative AI and Provider Solutions

* Ubie's growth has been accelerated by recent strategic investment and acceptance into Mayo Clinic Platform Accelerate program * Ubie's US Symptom Checker platform has seen 85% organic growth and a total user base of 4 million, helping deliver partnerships across patient advocacy and life sc...

2025-06-26 21:00 2275

Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia

SHANGHAI, June 26, 2025 /PRNewswire/ -- Alebund Pharmaceuticals  ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the database lock was achieved ...

2025-06-26 20:00 1835

Angel Yeast Set to Open Baiyang Biotechnology Park in Yichang in September

YICHANG, China, June 26, 2025 /PRNewswire/ -- Angel Yeast (SH:600298) a global leader in yeast manufacturing, has announced that its Baiyang Biotechnology Park ("the Park") located in the Yichang High-Tech Zone will complete construction and commence trial production i...

2025-06-26 20:00 1936

Global Orthodontists Gather in China to Explore Smartee's Mandibular Repositioning Technology

XI'AN, China , June 26, 2025 /PRNewswire/ -- Smartee Denti-Technology recently hosted international orthodontic experts and partners at a global symposium in Xi'an, China. Twenty-four Clinicians engaged in in-depth technical discussions on Smartee's Mandibular Repositioning Technology and toured ...

2025-06-26 13:24 1851

BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

* Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has ...

2025-06-26 08:38 5147

5K Walk Event in Michigan to Raise Money for Hidradenitis Suppurativa

NEW YORK, June 25, 2025 /PRNewswire/ -- On June 1, Dimora Medical, a continuous innovator in high-end medical care supplies, proudly participated as a sponsor in the HS Connect5K Walk. This event served not only as a fundraising effort but also as an opportunity for education about Hidradenitis S...

2025-06-26 03:27 1705

Medeologix Sets New Standard with 3-Week Lead Time for PET Heat Shrink Tubing

SAN JOSE, Calif., June 25, 2025 /PRNewswire/ -- Medeologix, a leading brand in medical device manufacturing, today announced a significant advancement in their production capabilities that slashes lead times for premium PET heat shrink tubing to just 3 weeks. This milestone is made possible by M...

2025-06-25 23:00 1681

Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today

TAIPEI and SAN DIEGO, June 25, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, held its 2025 Annual Shareholders' Meeting today, chaired by Chairman Mr.Benny T. Hu. The company delivered updates on its ongoing drug development programs, outl...

2025-06-25 19:00 2117

EDAN Establishes Mexico Subsidiary to Strengthen Presence in the Americas

MEXICO CITY, June 25, 2025 /PRNewswire/ -- EDAN Instruments, Inc. (300206.SZ), a healthcare company and medical device manufacturer, officially celebrated the opening of its new subsidiary, EDAN MEDICAL MÉXICO S de R.L. de C.V., with a ribbon-cutting ceremony held last Wednesday inMexico City. Th...

2025-06-25 18:07 1967

QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA

BRISBANE, Australia, June 25, 2025 /PRNewswire/ --   QBiotics CEO, Stephen Doyle, reflecting on Soft Tissue Sarcoma data * Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced S...

2025-06-25 18:05 1969

Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...

2025-06-24 22:02 2562

PanBrain Tech Unveils Breakthrough Brain-Computer Interface Device at BEYOND EXPO 2025 in Macau

MACAU, June 23, 2025 /PRNewswire/ -- Brain science technology company PanBrain Tech Co., Ltd. drew widespread attention at the BEYOND International Technology Innovation Expo 2025 inMacau with the debut of its flagship brain-computer interface (BCI) device, thePanBrain ...

2025-06-23 21:00 4170

OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer

PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced the appointment ofDimitry S.A. Nuyten, M.D.,...

2025-06-23 19:55 1632

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that results from an ...

2025-06-23 10:01 2191

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collabora...

2025-06-23 08:03 2022
1 ... 30313233343536 ... 308

Week's Top Stories